In the first week of December, there was a 70 per cent jump in the number of lab-confirmed influenza cases in Alberta, along ...
The strong immune response was confirmed in CHIKV-naïve children with a 94.7% seroresponse rate (full dose) at Day 360. The vaccine was well tolerated in children aged one to eleven years regardless ...
Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best biotech stocks to buy, according to Wall Street analysts. On December 8, the company confirmed the dosing of the first patients in its Phase 3 OPUS trial ...
Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult ...
Stockhead on MSN
Health Check: Cogstate suffers a nasty share price head knock, but its future ‘has never looked brighter’
The neurological monitoring house says current half revenue - and earnings - have been slower than expected because of timing ...
Investing.com -- Immuron Ltd ADR (NASDAQ:IMRN) stock plunged 24.5% in premarket trading Wednesday after the company announced that a clinical trial evaluating an ETEC hyperimmune bovine colostrum ...
TipRanks on MSN
Why is Immuron stock (IMRN) down today?
Immuron (IMRN) stock fell hard on Wednesday after the biopharmaceutical company announced results from the Uniformed Services ...
Steffini Stalos, DO, FCAP, is a pathology and lab medicine physician. She is also the chief medical officer of the lab consultancy firm Blood Associates, LLC. Most flu vaccines are made with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback